AR128389A1 - Anticuerpos anti-btla y usos de los mismos en el tratamiento del cáncer - Google Patents
Anticuerpos anti-btla y usos de los mismos en el tratamiento del cáncerInfo
- Publication number
- AR128389A1 AR128389A1 ARP230100218A ARP230100218A AR128389A1 AR 128389 A1 AR128389 A1 AR 128389A1 AR P230100218 A ARP230100218 A AR P230100218A AR P230100218 A ARP230100218 A AR P230100218A AR 128389 A1 AR128389 A1 AR 128389A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- btla
- antigen
- subject
- binding fragment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 abstract 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 abstract 1
- 102000053464 human BTLA Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen anticuerpos anti-BTLA y fragmentos de unión a antígeno de los mismos. Además, se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, y métodos para producir los anticuerpos y usar los anticuerpos para el tratamiento o la prevención del cáncer en un sujeto que lo necesita. Reivindicación 1: Un anticuerpo monoclonal aislado o su fragmento de unión a antígeno que comprende una región determinante de complementariedad de cadena pesada 1 (HCDR1), HCDR2, HCDR3, una región determinante de complementariedad de cadena ligera 1 (LCDR1), LCDR2, y LCDR3, que tienen las secuencias de polipéptidos de: (1) SEQ ID Nº 7, 8, 153, 10, 11, y 12, respectivamente; o (2) SEQ ID Nº 1, 2, 3, 4, 5, y 6, respectivamente; donde el anticuerpo o su fragmento de unión a antígeno se une específicamente al atenuador de linfocitos B y T (BTLA), preferentemente BTLA humano, opcionalmente, dicho anticuerpo monoclonal o su fragmento de unión a antígeno no es natural. Reivindicación 30: Un método para determinar el nivel de BTLA en un sujeto, donde el método comprende: a. obtener una muestra del sujeto; b. poner en contacto la muestra con un anticuerpo monoclonal aislado o su fragmento de unión a antígeno de cualquiera de las reivindicaciones 1 - 15; y c. determinar el nivel de BTLA en el sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022075097 | 2022-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128389A1 true AR128389A1 (es) | 2024-04-24 |
Family
ID=87470702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100218A AR128389A1 (es) | 2022-01-29 | 2023-01-30 | Anticuerpos anti-btla y usos de los mismos en el tratamiento del cáncer |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR128389A1 (es) |
| TW (1) | TW202340254A (es) |
| WO (1) | WO2023143565A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120090037A (ko) * | 2009-07-31 | 2012-08-16 | 메다렉스, 인코포레이티드 | Ｂｔｌａ에 대한 완전 인간 항체 |
| CN108925136B (zh) * | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体 |
| JOP20190261A1 (ar) * | 2017-05-19 | 2019-11-05 | Lilly Co Eli | أجسام مضادة لعامل مساعد لـ btla واستخداماتها |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| US11384146B2 (en) * | 2019-04-01 | 2022-07-12 | Curia Ip Holdings, Llc | BTLA-binding antibodies for modulating immune response and treating disease |
-
2023
- 2023-01-29 WO PCT/CN2023/073700 patent/WO2023143565A1/en unknown
- 2023-01-30 TW TW112103122A patent/TW202340254A/zh unknown
- 2023-01-30 AR ARP230100218A patent/AR128389A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023143565A1 (en) | 2023-08-03 |
| TW202340254A (zh) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| RU2011121818A (ru) | Способ иммунологического анализа белка cxcl1 человека | |
| AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
| AR072039A1 (es) | Anticuerpos contra el virus de la hepatitis c | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| AR105978A1 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp) y métodos de uso de las moléculas | |
| AR119268A1 (es) | Métodos de purificación de anticuerpos y composiciones de estos | |
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| PE20230389A1 (es) | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas | |
| AR128389A1 (es) | Anticuerpos anti-btla y usos de los mismos en el tratamiento del cáncer | |
| PE20221337A1 (es) | Anticuerpos trem2 y usos de estos | |
| RU2011104709A (ru) | Фармацевтическая композиция для лечения и предупреждения рака | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| EA202192508A1 (ru) | Способы получения композиций антитела к фно | |
| AR127273A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos |